Rigel Pharmaceuticals, Inc.
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×0.70 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×0.70 | 3 |
Strategy profile
Based on 7 disclosed transactions, Rigel Pharmaceuticals, Inc. concentrates its licensing activity in Oncology, Hematology. Rigel Pharmaceuticals, Inc. pays a 0.70x discount to market median, with the strongest premiums in Oncology (0.70x). Their most common deal structure is License, with an average disclosed value of $313M. Most recent activity: 2026.
Premium by therapeutic area
How Rigel Pharmaceuticals, Inc. pays relative to peer medians in each TA
Pipeline coverage & gaps
Rigel Pharmaceuticals, Inc. has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 6 | $50M | $346M |
| Acquisition | 1 | $15M | $118M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | VEPPANU (vepdegestrant) | Arvinas, Inc. | breast cancer | approved | $70M | $390M |
| 2026 | VEPPANU (vepdegestrant) | Arvinas and Pfizer | ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer | approved | $70M | $405M |
| 2026 | vepdegestrant | Arvinas, Inc. / Pfizer Inc. | ER+, HER2-negative, ESR1-mutated advanced or metastatic breast cancer | approved | $70M | $405M |
| 2026 | Vepdegestrant (ARV-471 / VEPPANU) | Arvinas | HR-positive advanced or metastatic breast cancer | approved | $85M | $405M |
| 2024 | GAVRETO (pralsetinib) | Blueprint Medicines Corporation | RET fusion-positive metastatic nsclc and advanced or metastatic thyroid cancer | approved | $15M | $118M |
| 2022 | Olutasidenib | Forma Therapeutics | relapsed/refractory AML (IDH1-mutant) | approved | $2M | $235M |
| 2022 | olutasidenib (FT-2102) | Forma Therapeutics | acute myeloid leukemia (AML) | approved | $2M | $236M |
How this is computed
For each Rigel Pharmaceuticals, Inc. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.660, clamped to [0.7, 1.5].